IMPLEXIS LTD
- Company typePrivate
- Founded2025
- HeadquartersLondon, United Kingdom
- Headcount—
- GTM typeB2B
- OfferingSoftware
IMPLEXIS LTD firmographics
Firmographics- Name
- IMPLEXIS LTD
- Legal name
- Implexis Ltd
- Website
- https://implexis.ai
- Company type
- Private
- Founded year
- 2025
- Operating status
- Operating
- Ownership category
- akta.pro rank
IMPLEXIS LTD industry classification
Industry- Product category
- Pharmaceutical Formulation Development Software
- NAICS
- Software Publishers (513210)
- SIC
- Services-Prepackaged Software (7372)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where IMPLEXIS LTD is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
IMPLEXIS LTD business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales
Revenue model
- Platform Software Services: SaaS-based access to proprietary formulation development platform. The company appears to offer software services to pharmaceutical companies for drug formulation development, likely through subscription or usage-based licensing.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
IMPLEXIS LTD product offering
Product offeringCore offering
Implexis Ltd sells a proprietary SaaS platform that automates drug formulation development for pharmaceutical companies. Users create and manage formulation experiments through the platform, configure excipients and constraints, define search spaces, upload pre-defined experimental data, and run multi-objective or single-objective optimization models to discover optimal formulations faster than traditional trial-and-error methods.
Product overview
Implexis is a formulation development platform comprising a proprietary core platform and multiple integrated modules. The platform is designed to accelerate drug formulation development through automation. The product portfolio includes the core Implexis Platform, a Dashboard module for monitoring experiments, an Experiments module for managing formulation development workflows (covering basic information, excipients configuration, constraints and optimization settings), and a Settings module for platform administration. Users can configure search space parameters, define materials and constraints, upload pre-defined experimental data, and select between Multiple Objectives or Single Objective optimization models.
Differentiator
Problem solved
Functional benefit
Products and services
- Implexis Platform A proprietary SaaS platform that automates drug formulation development for pharmaceutical and biotech companies. Users configure formulation experiments, set excipients and constraints, define search spaces, upload pre-defined experimental data, and run multi-objective or single-objective optimization models to reduce time-to-market and minimize experimental costs.
Quantifiable outcome
- Reduced time-to-market for drug formulations
- +2 more outcomes
Companies that use IMPLEXIS LTD
Customer profileSegments1 record
Ideal customer profiles1 record
IMPLEXIS LTD technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature4 records
IMPLEXIS LTD partnerships and signals
Strategic signalScale indicators1 record
Recent moves3 records
Expansion highlights2 records
IMPLEXIS LTD competitors and assessment
Company assessmentDirect peers
- Certara: Certara offers drug development software including Simcyp for PBPK and formulation prediction, widely used by pharmaceutical companies. It is a direct competitor in the pharmaceutical formulation modeling and drug development software market.
- Schrödinger: Schrödinger provides computational chemistry and physics-based simulation software used by pharma for molecular design, including formulation and materials modeling. It is the most established AI/physics platform in drug discovery and directly competes for the same R&D budget that Implexis targets in formulation development.
- OpenEye Scientific: OpenEye (now part of Cadence) provides molecular modeling and cheminformatics software widely used in pharma R&D including formulation-related property prediction. Comparable to Implexis in offering computational tools for pharmaceutical scientists.
- Simulations Plus: Simulations Plus provides modeling and simulation software for pharmaceutical R&D, including GastroPlus for oral absorption and formulation support. It is a direct competitor serving pharmaceutical formulation scientists with predictive software.
- ACD/Labs: ACD/Labs offers analytical and formulation informatics software used by pharmaceutical chemists for property prediction and formulation decision support. It is a direct peer providing software tools specifically targeting pharmaceutical formulation workflows.
Emerging players
- Benchling: Benchling offers a cloud-based R&D platform for life sciences including ELN, registration, and workflow management used by pharma and biotech. Comparable as a SaaS platform for pharmaceutical scientists, but broader in scope than Implexis' formulation-specific tooling.
- Insilico Medicine: Insilico Medicine applies AI to pharmaceutical R&D across drug discovery and development. Comparable as an AI-native life sciences platform targeting pharma, but with broader drug discovery focus rather than formulation specialization.
- TetraScience: TetraScience provides a data cloud platform for scientific R&D data in life sciences, including pharma lab data pipelines. Comparable in providing SaaS infrastructure for pharmaceutical R&D workflows, but focused on data layer rather than formulation optimization specifically.
- Dotmatics: Dotmatics provides an R&D informatics platform for scientific data management and workflow automation across pharma discovery and development. It is comparable in serving pharmaceutical scientists with software that structures experimental workflows, though broader than Implexis' formulation focus.
Broad incumbents
- Dassault Systèmes BIOVIA: BIOVIA is Dassault Systèmes' enterprise scientific software suite covering molecular modeling, lab informatics, and formulation workflows for large pharma. It is a broad incumbent offering overlapping capabilities versus Implexis but as part of a much larger enterprise portfolio.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
IMPLEXIS LTD financial estimates
Financial estimateRevenue estimate
Valuation estimate
IMPLEXIS LTD leadership team
Management profileNumber of profiles
Profiles5 records
IMPLEXIS LTD funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
IMPLEXIS LTD M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about IMPLEXIS LTD
What does IMPLEXIS LTD do?
Implexis Ltd sells a proprietary SaaS platform that automates drug formulation development for pharmaceutical companies. Users create and manage formulation experiments through the platform, configure excipients and constraints, define search spaces, upload pre-defined experimental data, and run multi-objective or single-objective optimization models to discover optimal formulations faster than traditional trial-and-error methods.
Is IMPLEXIS LTD a public or private company?
IMPLEXIS LTD is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was IMPLEXIS LTD founded?
IMPLEXIS LTD was founded in 2025.
Where is IMPLEXIS LTD based?
IMPLEXIS LTD is headquartered in London, United Kingdom, in the Europe region.
How does IMPLEXIS LTD make money?
One revenue line is on record: platform Software Services.
Who are IMPLEXIS LTD's main competitors?
Direct peers on record are Certara, Schrödinger, OpenEye Scientific, Simulations Plus and ACD/Labs. Emerging players are Benchling, Insilico Medicine, TetraScience and Dotmatics. Dassault Systèmes BIOVIA is listed as a broad incumbent.
Does IMPLEXIS LTD have an API?
No public API is recorded for IMPLEXIS LTD.
What industry is IMPLEXIS LTD in?
IMPLEXIS LTD's product category is Pharmaceutical Formulation Development Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 513210 and its SIC code is 7372.